Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2Lymphoid 1

Conditions

Myelodysplastic Syndromes 159Leukemia, Myeloid, Acute 141Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67Myeloproliferative Disorders 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Primary Myelofibrosis 47Leukemia, Myelomonocytic, Chronic 40Lymphoma, Non-Hodgkin 36Leukemia 26Polycythemia Vera 23Hodgkin Disease 23Myelodysplastic-Myeloproliferative Diseases 21Multiple Myeloma 20Thrombocythemia, Essential 19Hematologic Neoplasms 19Leukemia, Lymphocytic, Chronic, B-Cell 18Neoplasms 17Leukemia, Biphenotypic, Acute 15Anemia, Refractory, with Excess of Blasts 14Sarcoma 13Histiocytosis, Langerhans-Cell 13Glioma 13Neuroblastoma 12Hematologic Diseases 12Wilms Tumor 11Rhabdoid Tumor 11Recurrence 11Osteosarcoma 11Neuroectodermal Tumors, Primitive, Peripheral 11Medulloblastoma 11

Interventions

nilotinib 2asciminib 2bosutinib 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Philadelphia Chromosome × Myeloid × 90 days × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-05-27

ASC4START

Novartis

Phase 3 Active not recruiting
568 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡